CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera…

By M. Pfreundschuh, L. Trümper, A. Osterborg, R. Pettengell, M. Trněný, K. Imrie, D. Ma, D. Gill, J. Walewski, P. Zinzani and 14 more. The Lancet Oncology, 2006

1,936 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/b4fb838b12c25b8759469d194a3e36c2733e50a1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Ng
2. C. Gisselbrecht
3. B. Glass
4. C. Moskowitz
5. M. Trněný
6. N. Mounier
7. Devinder Singh Gill
8. J. Brière

Citations in the corpus

• Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. (2010, methodology): “Because DHAP has been widely used all over the world and was the salvage regimen of the PARMA study, it was used here as comparator.(5,12) Both regimens were supplemented with rituximab, which has been shown to improve treatment results of patients with relapsed DLBCL(11-13) not previously treated w”
• Diffuse large B-cell lymphoma. (2007, methodology): “The MInT study compared six cycles of R-CHOP-like chemotherapy with CHOPlike, in young patients with a low-risk DLBCL [ 7 ].”